Abstract: Embodiments of the disclosure provide a method and a device for processing a portrait image, the method includes: acquiring a to-be-processed portrait image; inputting the to-be-processed portrait image into an image processing model, and acquiring a head smear image output by the image processing model, where the image processing model is configured to smear a hair area of a portrait located above a preset boundary in the portrait image, and the image processing model is generated by training a sample data set of a sample portrait image and a sample head smear image corresponding to the sample portrait image; rendering the head smear image with a head effect material to obtain a portrait image added with an effect; and displaying the portrait image added with the effect.

Abstract: A system and method for capturing resource usage information in a network for namespaces in which pods operate are described herein. A data structure specifies a topology that includes a gateway and routing addresses in a network whose usage is to be captured. The data structure is provided to an API of a master node controlling the pods. A controller in the master node enforces the data structure and reports results back to the API.

Abstract: The present invention relates to crystalline polymorphs of an echinocandin antifungal agent and novel methods for their preparation.

Abstract: The present disclosure relates to polymorphic forms of the compound methyl (3R,6S)-6-amino-sulfonylamino-1-(thiazol-2-yl)-3-(2,3,4-trifluorophenyl)-3,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-4-formate (compound 1). The present disclosure further relates to a pharmaceutical composition and pharmaceutical use and a preparation method of the polymorphic forms of compound 1.

Abstract: The present disclosure relates to polymorphic forms of the compound methyl (3R,6S)-6-amino-sulfonylamino-1-(thiazol-2-yl)-3-(2,3,4-trifluorophenyl)-3,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-4-formate (compound 1). The present disclosure further relates to a pharmaceutical composition and pharmaceutical use and a preparation method of the polymorphic forms of compound 1.

Abstract: A sensor is compensated by selectively activating a temperature element to drive temperature within the thermal envelope encompassing the sensor towards an operating temperature and applying a compensation to output of the sensor based at least in part on the operating temperature. The initial ambient temperature is estimated and the operating temperature is selected from a set of predetermined temperatures based on the estimate. The current ambient temperature is estimated and a new operating temperature selected when the current ambient temperature is within a threshold of the operating temperature. Correspondingly, the temperature element is selectively activated to drive temperature within the thermal envelope towards the new operating temperature and an appropriate compensation is applied to the sensor output.

Abstract: A sensor may be compensated by selectively activating a temperature element to drive temperature within the thermal envelope encompassing the sensor towards an operating temperature and applying a compensation to output of the sensor based at least in part on the operating temperature. The initial ambient temperature may be estimated and the operating temperature may be selected from a set of predetermined temperatures based on the estimate. The current ambient temperature may be estimated and a new operating temperature selected when the current ambient temperature is within a threshold of the operating temperature. Correspondingly, the temperature element may be selectively activated to drive temperature within the thermal envelope towards the new operating temperature and an appropriate compensation may be applied to the sensor output.

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.